Experimental CAR-T Therapy Drives Complete Remission in a 3-Year-Old's Liver Cancer
A 3-year-old with metastatic hepatoblastoma achieved complete remission after two outpatient infusions of an experimental CAR T cell therapy targeting glypican-3 and engineered to express IL-15 and IL-21. The cancer disappeared after the second dose and remained cancer-free at 12 months, with no major cytokine release syndrome or other serious side effects. The treatment is part of the CARE trial in early phase testing, and researchers emphasize the need for further study in more patients with glypican-3+ solid tumors.